Updating the probability of study success for combination therapies using related combination study data

被引:1
|
作者
Graham, Emily [1 ,5 ]
Harbron, Chris [2 ]
Jaki, Thomas [3 ,4 ]
机构
[1] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster, England
[2] Roche Pharmaceut, Welwyn Garden City, England
[3] Univ Regensburg, Regensburg, Germany
[4] Univ Cambridge, MRC Biostat Unit, Cambridge, England
[5] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster LA1 4YF, England
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
Combination therapies; clinical trials; probability of success; Bayesian; assurance; CLINICAL-TRIALS; PHASE-II; TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; POWER; END;
D O I
10.1177/09622802231151218
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Combination therapies are becoming increasingly used in a range of therapeutic areas such as oncology and infectious diseases, providing potential benefits such as minimising drug resistance and toxicity. Sets of combination studies may be related, for example, if they have at least one treatment in common and are used in the same indication. In this setting, value can be gained by sharing information between related combination studies. We present a framework that allows the study success probabilities of a set of related combination therapies to be updated based on the outcome of a single combination study. This allows us to incorporate both direct and indirect data on a combination therapy in the decision-making process for future studies. We also provide a robustification that accounts for the fact that the prior assumptions on the correlation structure of the set of combination therapies may be incorrect. We show how this framework can be used in practice and highlight the use of the study success probabilities in the planning of clinical studies.
引用
收藏
页码:712 / 731
页数:20
相关论文
共 50 条
  • [21] A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
    Parrondo, Ricardo D.
    Dutta, Navnita
    Laplant, Betsy R.
    Elliott, Jamie
    Fernandez, Andre
    Zimmerman, Ashley
    Cicco, Gina
    Han, Bing
    Heslop, Keisha
    Chapin, Dustin
    Sher, Taimur
    Roy, Vivek
    Rasheed, Ahsan
    Das, Saurav
    Chanan-Khan, Asher A.
    Paulus, Aneel
    Ailawadhi, Sikander
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (05) : 1825 - 1829
  • [22] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
    Gowin, K.
    Kosiorek, H.
    Dueck, A.
    Mascarenhas, J.
    Hoffman, R.
    Reeder, C.
    Camoriano, J.
    Tibes, R.
    Gano, K.
    Palmer, J.
    Mesa, R.
    LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
  • [23] Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
    Choi, Yunjung
    Yun, Mi Sun
    Lim, Sang Hee
    Lee, Jeeyun
    Ahn, Jin-Hee
    Kim, Yu Jung
    Park, Kyong Hwa
    Park, Young Suk
    Lim, Ho Yeong
    An, Hyonggin
    Suh, Dong-Churl
    Kim, Yeul Hong
    CANCER RESEARCH AND TREATMENT, 2018, 50 (01): : 175 - 182
  • [24] Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study
    Di Giannatale, Angela
    Dias-Gastellier, Nathalie
    Devos, Annick
    Mc Hugh, Kieran
    Boubaker, Ariane
    Courbon, Frederic
    Verschuur, Arnaud
    Ducassoul, Stephane
    Malekzadeh, Katty
    Casanova, Michela
    Amoroso, Loredana
    Chastagner, Pascal
    Zwaan, Christian M.
    Munzer, Caroline
    Aerts, Isabelle
    Landman-Parker, Judith
    Riccardi, Riccardo
    Le Deley, Marie-Cecile
    Geoerger, Birgit
    Rubie, Herve
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 170 - 177
  • [25] A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer
    Takaki Yoshikawa
    Akira Tsuburaya
    Ken Shimada
    Atsushi Sato
    Makoto Takahashi
    Wasaburo Koizumi
    Yasuo Yoshizawa
    Kazuhito Nabeshima
    Masayuki Kimura
    Kiyoshi Hataya
    Osamu Kobayashi
    Gastric Cancer, 2009, 12 : 212 - 218
  • [26] A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer
    Yoshikawa, Takaki
    Tsuburaya, Akira
    Shimada, Ken
    Sato, Atsushi
    Takahashi, Makoto
    Koizumi, Wasaburo
    Yoshizawa, Yasuo
    Nabeshima, Kazuhito
    Kimura, Masayuki
    Hataya, Kiyoshi
    Kobayashi, Osamu
    GASTRIC CANCER, 2009, 12 (04) : 212 - 218
  • [27] A Phase 2 Study of Cetuximab in Combination With Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Nonsmall Cell Lung Cancer
    Kim, Edward S.
    Mauer, Ann M.
    William, William N., Jr.
    Tran, Hai T.
    Liu, Diane
    Lee, Jack J.
    Windt, Paul
    Hong, Waun K.
    Vokes, Everett E.
    Herbst, Roy S.
    CANCER, 2009, 115 (08) : 1713 - 1722
  • [28] Experimental study of the effects on apoptosis of docetaxel alone and in combination with irradiation
    Matsuura, M
    Hasegawa, M
    Hayakawa, K
    Kawashima, M
    Nasu, S
    Nakamura, Y
    Hayakawa, K
    Mitsuhashi, N
    Niibe, H
    ONCOLOGY REPORTS, 2000, 7 (02) : 289 - 293
  • [29] A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma
    Zhou, Rui
    Zhou, Ping
    Yu, Yi-Feng
    Lin, Qin
    Wu, San-Gang
    CURRENT CANCER DRUG TARGETS, 2024, 24 (03) : 319 - 327
  • [30] A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
    Schweizer, Michael T.
    Haugk, Kathleen
    McKiernan, Jozefa S.
    Gulati, Roman
    Cheng, Heather H.
    Maes, Jessica L.
    Dumpit, Ruth F.
    Nelson, Peter S.
    Montgomery, Bruce
    McCune, Jeannine S.
    Plymate, Stephen R.
    Yu, Evan Y.
    PLOS ONE, 2018, 13 (06):